Modulation of Cannabinoid Receptor Activation as a Neuroprotective Strategy for EAE and Stroke

Archambault AS, Sim J et al (2005) Defining antigen-dependent stages of T cell migration from the blood to the central nervous system parenchyma. Eur J Immunol 35(4):1076–1085. doi:10.1002/eji.200425864 Ashton JC, Rahman RM et al (2007) Cerebral hypoxia–ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neurosci Lett 412(2):114–117. doi:10.1016/j.neulet.2006.10.053 Baker D, Pryce G et al (2000) Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404(6773):84–87. doi:10.1038/35003583 Baker D, Pryce G et al (2001) Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15(2):300–302 Batkai S, Osei-Hyiaman D et al (2007) Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 21(8):1788–1800. doi:10.1096/fj.06-7451com Becher B, Bechmann I et al (2006) Antigen presentation in autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. J Mol Med 84(7):532–543. doi:10.1007/s00109-006-0065-1 Berger C, Schmid PC et al (2004) Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia. J Neurochem 88(5):1159–1167. doi:10.1046/j.1471-4159.2003.02244.x Correa F, Mestre L et al (2005) Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. Br J Pharmacol 145(4):441–448. doi:10.1038/sj.bjp.0706215 Dawson DA, Ruetzler CA et al (1996) Polymorphonuclear leukocytes and microcirculatory perfusion in acute stroke in the SHR. Keio J Med 45(3):248–252 discussion 252–253 Dittel BN (2008) Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. Br J Pharmacol 153(2):271–276. doi:10.1038/sj.bjp.0707493 Dutka AJ, Hallenbeck JM et al (1987) A brief episode of severe arterial hypertension induces delayed deterioration of brain function and worsens blood flow after transient multifocal cerebral ischemia. Stroke 18(2):386–395 Dutka AJ, Kochanek P et al (1988) Air embolism may cause unrecognized ischemia of the gray–white junction. Undersea Biomed Res 15(2):99–106 Dutka AJ, Kochanek PM et al (1989) Influence of granulocytopenia on canine cerebral ischemia induced by air embolism. Stroke 20(3):390–395 Eljaschewitsch E, Witting A et al (2006) The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. Neuron 49(1):67–79. doi:10.1016/j.neuron.2005.11.027 Golech SA, McCarron RM et al (2004) Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132(1):87–92. doi:10.1016/j.molbrainres.2004.08.025 Greter M, Heppner FL et al (2005) Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11(3):328–334. doi:10.1038/nm1197 Hallenbeck JM, Dutka AJ et al (1986) Polymorphonuclear leukocyte accumulation in brain regions with low blood flow during the early postischemic period. Stroke 17(2):246–253 Hallenbeck JM, Dutka AJ et al (1988) Stroke risk factors prepare rat brainstem tissues for modified local Shwartzman reaction. Stroke 19(7):863–869 Hayakawa K, Mishima K et al (2004) Cannabidiol prevents infarction via the non-CB1 cannabinoid receptor mechanism. Neuroreport 15(15):2381–2385. doi:10.1097/00001756-200410250-00016 Heppner FL, Greter M et al (2005) Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 11(2):146–152. doi:10.1038/nm1177 Hickey WF, Kimura H (1988) Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science 239(4837):290–292. doi:10.1126/science.3276004 Jarai Z, Wagner JA et al (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A 96(24):14136–14141. doi:10.1073/pnas.96.24.14136 Jin KL, Mao XO et al (2000) CB1 cannabinoid receptor induction in experimental stroke. Ann Neurol 48(2):257–261. doi:10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.0.CO;2-P Klein TW (2005) Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5(5):400–411. doi:10.1038/nri1602 Klein TW, Cabral GA (2006) Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. J Neuroimmune Pharmacol 1:50–64. doi:10.1007/s11481-005-9007-x Klein TW, Newton C et al (2004) Cannabinoid receptors and T helper cells. J Neuroimmunol 147(1–2):91–94. doi:10.1016/j.jneuroim.2003.10.019 Kochanek PM, Hallenbeck JM (1992) Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 23(9):1367–1379 Kochanek PM, Dutka AJ et al (1987a) Indomethacin, prostacyclin, and heparin improve postischemic cerebral blood flow without affecting early postischemic granulocyte accumulation. Stroke 18(3):634–637 Kochanek PM, Dutka AJ et al (1987b) Platelet activating factor receptor blockade enhances recovery after multifocal brain ischemia. Life Sci 41(24):2639–2644. doi:10.1016/0024-3205(87)90278-5 Kochanek PM, Dutka AJ et al (1988) Effects of prostacyclin, indomethacin, and heparin on cerebral blood flow and platelet adhesion after multifocal ischemia of canine brain. Stroke 19(6):693–699 Leker RR, Gai N et al (2003) Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke 34(8):2000–2006. doi:10.1161/01.STR.0000079817.68944.1E Little PJ, Compton DR et al (1988) Pharmacology and stereoselectivity of structurally novel cannabinoids in mice. J Pharmacol Exp Ther 247(3):1046–1051 Louw DF, Yang FW et al (2000) The effect of delta-9-tetrahydrocannabinol on forebrain ischemia in rat. Brain Res 857(1–2):183–187. doi:10.1016/S0006-8993(99)02422-1 Lu T, Newton C et al (2006) Cannabinoid treatment suppresses the T-helper cell-polarizing function of mouse dendritic cells stimulated with Legionella pneumophila infection. J Pharmacol Exp Ther 319(1):269–276. doi:10.1124/jpet.106.108381 Lyman WD, Sonett JR et al (1989) Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23(1):73–81. doi:10.1016/0165-5728(89)90075-1 Mackie K (2006) Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101–122. doi:10.1146/annurev.pharmtox.46.120604.141254 Maresz K, Pryce G et al (2007) Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB(1) on neurons and CB(2) on autoreactive T cells. Nat Med 13(4):492–497. doi:10.1038/nm1561 McCollum L, Howlett AC et al (2007) Anandamide-mediated CB1/CB2 cannabinoid receptor-independent nitric oxide production in rabbit aortic endothelial cells. J Pharmacol Exp Ther 321(3):930–937. doi:10.1124/jpet.106.117549 McMahon EJ, Bailey SL et al (2005) Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 11(3):335–339. doi:10.1038/nm1202 McMahon EJ, Bailey SL et al (2006) CNS dendritic cells: critical participants in CNS inflammation. Neurochem Int 49(2):195–203. doi:10.1016/j.neuint.2006.04.004 Mechoulam R, Fride E et al (1998) Endocannabinoids. Eur J Pharmacol 359(1):1–18. doi:10.1016/S0014-2999(98)00649-9 Muthian S, Rademacher DJ et al (2004) Anandamide content is increased and CB1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience 129(3):743–750. doi:10.1016/j.neuroscience.2004.08.044 Nagayama T, Sinor AD et al (1999) Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 19(8):2987–2995 Ni X, Geller EB et al (2004) Win 55212–2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10(2):158–164. doi:10.1191/1352458504ms1009oa O'Sullivan SE, Kendall DA et al (2004a) Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br J Pharmacol 141(5):803–812. doi:10.1038/sj.bjp.0705643 O'Sullivan SE, Kendall DA et al (2004b) Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br J Pharmacol 142(3):435–442. doi:10.1038/sj.bjp.0705810 Pacher P, Hasko G (2008) Endocannabinoids and cannabinoid receptors in ischaemia–reperfusion injury and preconditioning. Br J Pharmacol 153(2):252–262. doi:10.1038/sj.bjp.0707582 Pacher P, Batkai S et al (2006) The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58(3):389–462. doi:10.1124/pr.58.3.2 Parmentier-Batteur S, Jin K et al (2002) Increased severity of stroke in CB1 cannabinoid receptor knock-out mice. J Neurosci 22(22):9771–9775 Pertwee RG (1999) Medical uses of cannabinoids: the way forward. Addiction 94(3):317–320. doi:10.1080/09652149933801 Rajesh M, Pan H et al (2007) Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 82(6):1382–1389. doi:10.1189/jlb.0307180 Ralevic V, Kendall DA et al (2002) Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci 71(22):2577–2594. doi:10.1016/S0024-3205(02)02086-6 Schmid PC, Krebsbach RJ et al (1995) Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett 375(1–2):117–120. doi:10.1016/0014-5793(95)01194-J Shouman B, Fontaine RH et al (2006) Endocannabinoids potently protect the newborn brain against AMPA-kainate receptor-mediated excitotoxic damage. Br J Pharmacol 148(4):442–451. doi:10.1038/sj.bjp.0706755 Sommer C, Schomacher M et al (2006) Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. Acta Neuropathol 112(3):277–286. doi:10.1007/s00401-006-0110-8 Steinman L (1996) Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85(3):299–302. doi:10.1016/S0092-8674(00)81107-1 Stella N (2004) Cannabinoid signaling in glial cells. Glia 48(4):267–277. doi:10.1002/glia.20084 van der Stelt M, Veldhuis WB et al (2001a) Neuroprotection by Delta9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci 21(17):6475–6479 van der Stelt M, Veldhuis WB et al (2001b) Exogenous anandamide protects rat brain against acute neuronal injury in vivo. J Neurosci 21(22):8765–8771 Weaver M, Leshley K et al (2002) LEX032, a novel recombinant serpin, protects the brain after transient focal ischemia. Microvasc Res 63(3):327–334. doi:10.1006/mvre.2002.2405 Wiley JL, Beletskaya ID et al (2002) Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J Pharmacol Exp Ther 301(2):679–689. doi:10.1124/jpet.301.2.679 Wirguin I, Mechoulam R et al (1994) Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology 28(3):209–214. doi:10.1016/0162-3109(94)90056-6 Witting A, Chen L et al (2006) Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc Natl Acad Sci U S A 103(16):6362–6367. doi:10.1073/pnas.0510418103 Yuan M, Kiertscher SM et al (2002) Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol 133(1–2):124–131. doi:10.1016/S0165-5728(02)00370-3 Zhang M, Martin BR et al (2007) Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 27(7):1387–1396. doi:10.1038/sj.jcbfm.9600447 Zhang M, Martin BR et al (2008) Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 152(3):753–760. doi:10.1016/j.neuroscience.2008.01.022